GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction ...

A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...

WEIGHT loss, warding off dementia, ‘curing’ diabetes and now… anti-ageing powers? Is there anything the so-called fat jabs can’t do? While a medicine that reverses the clock would be a ...